Mushroom Gummies vs Chaga Mushrooms: Why Pilly Labs Is Leading the Functional Supplement Shift in 2025
Searches for 'mushroom gummies vs Chaga mushrooms' are exploding as health-conscious consumers compare formats, benefits, and brands in 2025. At the forefront of this trend is Pilly Labs — a supplement innovator gaining recognition for its high-potency, fruiting body–only formulas and its role in driving the mushroom wellness movement forward. This article explores the rise of mushroom gummies, how they compare to traditional Chaga capsules, and why more people are turning to Pilly Labs for a modern, research-informed approach to cognitive clarity, stress support, and weight-conscious living.
Introduction
Across social media, health forums, and nutrition podcasts in 2025, one comparison continues to dominate search queries: mushroom gummies vs Chaga mushrooms. While both options tap into the growing fascination with functional fungi, consumers are increasingly asking which format delivers more convenience, better ingredient transparency, and stronger support for goals like focus, metabolism, and daily stress balance. In the middle of this shift is Pilly Labs — a U.S.-based brand known for its 10:1 fruiting body mushroom extracts, flavor-forward delivery systems, and commitment to non-GMO, third-party-tested formulas. As demand for natural wellness tools accelerates, Pilly Labs is quickly becoming one of the most talked-about names in the mushroom supplement space, particularly for those seeking alternatives to traditional capsules and powders.
TL;DR: Why Mushroom Gummies Are Surging Past Chaga in 2025
Mushroom gummies have taken center stage in the functional supplement world — and Pilly Labs is helping lead that transition. While Chaga capsules remain popular for their antioxidant properties, gummies offer a more approachable, flavorful, and habit-forming experience. With increased attention on mood, metabolism, and mental clarity, many consumers are moving toward multi-mushroom blends like Pilly Labs Mushroom Extract Complex — a formula crafted specifically for modern wellness goals without the clinical overtones or confusing dosing often found in legacy formats.
In This Release, You'll Discover: How mushroom gummies and Chaga capsules compare in format, focus, and user adoption
What makes Pilly Labs' mushroom formulas different from standard extracts
The growing demand for functional supplements with cognitive, metabolic, and immune-supporting properties
Why fruiting body extracts matter — and how 10:1 potency ratios stack up against traditional options
Real-world reviews, success stories, and public commentary around gummies vs capsules
Tips for building a sustainable supplement routine based on your goals for energy, focus, and emotional resilience
Explore the Full Pilly Labs Mushroom Supplement Lineup
For those focused on multi-mushroom support, the Pilly Labs Mushroom Extract Complex offers a 10-mushroom formula designed with fruiting body extracts and clean-label transparency. If you're drawn to single-ingredient simplicity, Pilly Labs Chaga Mushroom Capsules provide a high-potency option for those exploring the historical benefits of Chaga supplementation.
The formulation has already gained national attention. One recent editorial spotlighted the Pilly Labs Chaga Mushroom Formula as a standout for its purity and potency. Others have recognized Pilly Labs gummies as a top mushroom supplement for men and women, especially for those seeking mood and energy balance. Even mainstream coverage is noting the rapid growth of mushroom gummies for anxiety support, with Pilly Labs mentioned among the early leaders shaping this evolving category.
Why interest in 'mushroom gummies' is surging in 2025
Mushroom gummies are no longer a fringe concept—they've gone mainstream. In 2025, searches for mushroom gummies have overtaken traditional queries for mushroom capsules and powders, according to Google Trends data aggregated from wellness-focused keywords. On TikTok, influencers are showcasing morning gummy rituals as part of 'anti-anxiety stack' routines and brain-boosting supplement hauls. On Reddit, the conversation has shifted from capsule absorption rates to flavor, texture, and which gummy blend feels most consistent. These trends highlight not just product curiosity, but a wider behavioral pivot toward convenience, routine-building, and wellness made simple.
Part of the appeal is generational. Many younger consumers associate capsule-based products with legacy supplement brands, while gummies feel accessible, modern, and easier to stay consistent with. The flavor component—especially fruit-forward formats like raspberry—also plays a psychological role, transforming supplement-taking from a chore into something habit-forming. In a crowded supplement market filled with unflavored powders and oversized pills, mushroom gummies are winning attention for their portability, pleasant taste, and functional overlap across use cases like focus, metabolism, immune support, and mood stabilization.
Even among supplement skeptics, mushroom gummies are starting to show up in 'starter stack' discussions. Consumers who wouldn't typically commit to a multi-ingredient capsule formula are more willing to test a 10-mushroom gummy blend, especially when it's positioned as food-based, low-risk, and backed by clean-label transparency. Whether driven by social media trends or ingredient exploration, the behavioral shift is clear: mushroom gummies have become the gateway format for functional fungi—and they're here to stay.
Pilly Labs' ingredient-first response to these trends
As interest in functional fungi continues to surge in 2025, Pilly Labs has positioned itself at the intersection of consumer demand, ingredient transparency, and modern formulation. Rather than following the crowded path of mycelium-on-grain capsules and generic extract blends, the brand has focused exclusively on full-spectrum fruiting body mushrooms—the part of the mushroom most recognized by consumers and studied in research circles for its rich profile of beta-glucans, antioxidants, and adaptogenic compounds. Every gummy and capsule produced by Pilly Labs is built around this ingredient-first philosophy, prioritizing clarity over complexity and formulation over marketing.
This approach is exemplified in the Pilly Labs Mushroom Extract Complex, a 10-mushroom formula built with a clean-label gummy base and no unnecessary fillers.
One of the key differentiators in the brand's approach is the decision to use a 10:1 fruiting body extract for each mushroom in its lineup. This ratio reflects a more concentrated yield, meaning that ten parts of raw mushroom are extracted into one part of bioactive content. While many companies use lower-potency blends or rely on mycelium grown on rice or oats, Pilly Labs has invested in a more rigorous sourcing and extraction process to meet the expectations of consumers seeking measurable transparency.
Just as importantly, Pilly Labs has committed to avoiding unnecessary additives, synthetic fillers, and low-value delivery methods. The brand's Mushroom Extract Complex Gummies are formulated with a clean-label base that includes glucose syrup, raspberry flavor, purple carrot juice concentrate, and natural pectin—intentionally chosen to create a taste-forward experience without compromising purity. This reflects the broader movement toward food-grade supplements that align with daily lifestyle choices, rather than clinical protocols or restrictive regimens.
By pairing this ingredient integrity with user-friendly formats, Pilly Labs offers a response that feels intuitive to today's wellness consumers. Whether the focus is on building better focus, maintaining balance under stress, or supporting weight-conscious routines, the formulation behind Pilly Labs supplements is engineered to reflect the values of modern supplementation: clean inputs, thoughtful delivery, and transparency at every step.
Curious why 10:1 fruiting body extracts are getting so much buzz? Try Pilly Labs and experience the real difference in concentration, transparency, and taste—crafted for today's ingredient-conscious consumer.
Ingredient spotlight – what's inside the formula
At the core of Pilly Labs' mushroom supplement strategy is a thoughtfully designed blend of ten functional mushrooms, each selected for its long-standing use in herbal traditions and its current role in the modern wellness conversation. Rather than relying on vague proprietary blends or powdered mycelium, Pilly Labs uses concentrated 10:1 fruiting body extracts for every ingredient—meaning the most nutrient-dense part of the mushroom is delivered in each dose, in a highly condensed form. This approach is increasingly favored by consumers who want to understand not just what's in their supplements, but why each ingredient is there and how it aligns with their health routines.
Maitake, often explored for its role in metabolic balance and traditional immune rituals, brings depth to the formula as one of the most frequently discussed mushrooms in Eastern wellness circles. Shiitake adds a familiar culinary profile while also being historically referenced for its nutrient content and circulatory relevance. Lion's Mane, widely featured in cognitive optimization conversations, is now among the most searched mushroom ingredients online—often linked to discussions around clarity, memory, and neural performance.
Reishi, long known in herbal folklore as the 'mushroom of longevity,' continues to generate interest on social platforms for its association with emotional balance and nightly wind-down routines. Cordyceps, with its energetic tone, is frequently mentioned in athletic recovery circles and among those interested in physical stamina through plant-based strategies. Chaga, a well-documented antioxidant-rich mushroom, has become a staple in both supplement and skincare categories due to its connection with cellular defense conversations.
Turkey Tail brings additional complexity, especially in discussions around gut health and resilience, while White Button offers familiar grounding in a formula filled with more exotic fungi. Black Fungus has been traditionally incorporated into diets across Asia for centuries, often tied to cultural wellness customs and circulatory awareness. Finally, Royal Sun Mushroom—sometimes referred to as Agaricus blazei—is frequently explored for its potential role in immune-focused daily routines and overall adaptogenic stacking.
Each of these mushrooms plays a distinct role in the Pilly Labs formula, not because of promised outcomes, but because of how they reflect centuries of herbal wisdom and current public curiosity. In combination, they offer a non-clinical but strategically diverse entry point into the evolving category of functional fungi—where tradition, trend, and formulation converge.
More people than ever are trading Chaga capsules for multi-mushroom gummies that actually taste good and deliver results. See why Pilly Labs is leading the charge in this wellness shift with a formula built for focus, calm, and momentum.
What Reddit, podcasts, and TikTok creators are saying
The rise of mushroom supplements has unfolded across platforms where modern wellness conversations thrive—especially Reddit, long-form podcasts, and TikTok creator channels. In 2025, these communities are not just discussing which brands they use, but how they build full-stack supplement routines that prioritize mental clarity, emotional balance, and low-maintenance consistency. Within this dialogue, mushroom gummies have become a featured element in morning and evening rituals, often described in the context of anti-anxiety gummies, focus blends, or sleep-stabilizing stacks.
On TikTok, creators are showcasing 'what I take every day' videos featuring raspberry-flavored mushroom gummies alongside hydration reminders and mindfulness habits. Rather than focusing on science or clinical trials, these videos center on user experience, taste, and routine-building—helping to normalize the integration of functional fungi into everyday wellness. Gummies from Pilly Labs have appeared in these routines, especially for their combination of clean-label appeal and diverse ingredient profile, which aligns with the aesthetic and functional expectations of wellness-focused audiences on social media.
Reddit communities such as those discussing nootropics, anxiety alternatives, and biohacking supplements are reflecting a similar shift. Instead of long debates about ingredient ratios or absorption rates, users are now talking about which gummy formulas they actually remember to take, how they feel more consistent using flavored formats, and why they've migrated from capsule-based mushroom stacks to blended gummies with multiple species in one dose. Many threads mention exploring mushroom gummies first before committing to more complex routines—demonstrating the role these supplements play as both entry point and anchor in a broader functional regimen.
Podcasts that cover health tech, neuro-enhancement, or the future of food are also spotlighting mushroom-based solutions. These conversations often explore themes like adaptogens, cognitive resilience, and the democratization of wellness through accessible formats. Gummies are frequently cited as an example of how once-niche ingredients like Reishi, Cordyceps, or Lion's Mane are now being delivered in ways that meet both lifestyle and psychological compliance—meaning people are more likely to stick with the product.
Across all platforms, the tone of conversation has moved away from hard science and toward practical integration. It's no longer just about whether mushrooms might help; it's about how they fit into real life. In that context, Pilly Labs' decision to lead with convenience, taste, and formulation transparency is increasingly aligned with what creators and consumers alike are saying they actually want.
Who might be drawn to this type of supplementation in 2025
The popularity of mushroom-based supplements in 2025 reflects a broader shift in how different types of consumers approach personal wellness. Rather than relying on traditional pharmaceuticals or aggressive performance enhancers, a growing number of individuals are exploring food-based, routine-friendly tools that fit within their daily lifestyle—and mushroom gummies are emerging as a preferred format. This is especially true for people seeking more than just symptom relief. They're looking for supplements that feel intuitive, accessible, and capable of supporting consistent habits over time.
Among early adopters are cognitive optimizers—individuals focused on mental clarity, daily focus, and task efficiency. These users are often immersed in knowledge work, entrepreneurship, or academic environments and are drawn to mushroom ingredients like Lion's Mane, Cordyceps, and Reishi as part of a larger nootropic exploration. Gummies appeal to this group not just because of their active compounds, but because of their ease of use and the ability to pair with other wellness habits like hydration, breathwork, or journaling.
Another key audience includes stress-aware professionals and remote workers navigating fast-paced routines without consistent structure. For these consumers, morning or midday mushroom gummies are used as part of a self-regulated rhythm—supporting emotional resilience, cognitive grounding, and overall calm. While individual responses vary, many see these gummies as a safer, food-forward addition to routines that prioritize clarity and balance without over-reliance on stimulants or synthetic solutions.
There's also increasing interest from fitness-minded individuals who are turning toward adaptogenic supplementation. These consumers often overlap with clean-eating circles and are highly ingredient-conscious. They tend to favor 10:1 fruiting body extracts, vegan formulations, and naturally flavored formats that align with their larger lifestyle philosophy. For them, mushroom gummies represent a way to support overall vitality and recovery without introducing unnecessary fillers or sugars that conflict with their performance goals.
Even those new to supplementation are showing curiosity, especially when they find formulas that are easy to understand, pleasant to consume, and backed by visible transparency. Whether the interest starts with a TikTok recommendation or a referral from a podcast host, Pilly Labs has positioned its mushroom supplements to meet the expectations of this modern audience—without requiring a background in biohacking or nutrition science.
The unifying theme across all these groups is a shared desire for supplementation that fits into life, not something that disrupts it. Mushroom gummies—particularly those with multi-ingredient synergy and clean-label execution—offer a low-friction way to build momentum toward better daily wellness. In this context, Pilly Labs is drawing attention not only for what it includes in its formulas, but for what it chooses to leave out.
Whether it's part of your anti-anxiety stack or a morning mindfulness habit, Pilly Labs mushroom gummies are designed to meet you where you are. Join the growing number of consumers transforming wellness into something joyful.
Spiritual optimization and functional fungi – 2025 market reflections
In 2025, functional mushroom supplements are increasingly intersecting with a broader movement that emphasizes inner clarity, emotional alignment, and cognitive grounding. This evolution has created a new category of consumers—individuals who view wellness not just through the lens of physical performance or metabolic health, but through a deeper connection to mindfulness, awareness, and adaptability. As a result, mushroom gummies have begun to appear in daily regimens that reflect both spiritual exploration and practical self-regulation.
The rise of pineal-focused content on social media, along with the growing popularity of 'detox-conscious' routines, has introduced mushrooms like Lion's Mane, Reishi, and Chaga into conversations far beyond traditional supplement circles. These ingredients are now being included in morning meditations, breathwork flows, and grounding rituals—not as clinical tools, but as accessible elements that match the tone and intention of inner optimization. Consumers aren't asking what mushrooms treat; they're asking how they feel when incorporating them into routines that prioritize presence and mental spaciousness.
This shift isn't limited to niche communities. Across podcasts, wellness summits, and TikTok compilations, there is increasing interest in how natural ingredients can enhance focus without overstimulation, promote emotional balance without sedation, and fit within rituals that blend nutrition, intention-setting, and environmental awareness. Functional fungi are being positioned as part of a new self-care language—one that replaces medicalized solutions with plant-based patterns that support adaptability in everyday life.
Pilly Labs has responded to this trend not by making promises, but by offering clarity in formulation. Its Mushroom Extract Complex is built around the idea that multi-ingredient synergy, natural flavor, and simplified dosing can support a different kind of wellness user—someone more concerned with rhythm and resonance than outcome metrics. The use of fruiting body extracts, vegan delivery systems, and low-friction formats like gummies aligns with this spiritualized wellness model, where the focus is on energy hygiene, not performance hacking.
As the market continues to evolve, functional mushroom supplements are expected to play a larger role in what analysts are calling the 'introspective wellness economy'—an emerging category that includes sleep hygiene, emotional tracking, conscious movement, and sensory modulation. Within this context, products like Pilly Labs' mushroom gummies are not just nutritional tools—they're cultural artifacts of a larger shift toward self-led, body-informed, and ritual-compatible supplementation.
Still using mycelium-filled capsules? Make the switch to clean-label, fruiting body–only formulas with Pilly Labs—backed by a commitment to clarity, not clinical jargon.
The public debate around mushroom supplements – signals, skepticism, and saturation
As mushroom supplements continue to expand into the mainstream, the public dialogue around their role in modern wellness is becoming increasingly layered. What started as a fringe interest in functional fungi has now become a full-blown cultural movement, with mushroom gummies and capsules appearing in everything from grocery store shelves to social media rituals. While many see this as a positive sign of innovation and accessibility, others are raising concerns about market saturation, overpromised benefits, and the distinction between trend and science.
Among supporters, mushroom supplementation represents a timely evolution in how people manage stress, energy, and cognitive rhythm. These advocates point to the ingredient transparency now found in leading formulas, the migration away from synthetic boosters, and the alignment between mushroom gummies and behavior-based wellness routines. They see mushroom-based blends as part of a larger shift toward food-grade supplementation—less about treating symptoms and more about sustaining resilience. In this context, gummies from brands like Pilly Labs are often cited as examples of what's working: clean formulations, no mycelium fillers, and multi-ingredient synergy delivered in an approachable format.
At the same time, a growing number of skeptics are voicing caution. Some question whether mushroom supplements are truly differentiated across brands or if many are simply repackaged versions of the same ingredient deck. Others express concern over exaggerated marketing language or the temptation to conflate ancient herbal associations with guaranteed outcomes. This group emphasizes the need for consumers to look past design, flavor, and influencer appeal—and instead verify sourcing practices, extraction methods, and actual concentration levels. Even well-meaning brands, they argue, must navigate a wellness economy that's increasingly crowded and difficult to audit.
Meanwhile, a neutral segment of consumers and industry observers continues to frame the conversation in terms of integration and identity. For them, the real question isn't whether mushrooms 'work,' but whether they fit into an individual's evolving relationship with routine. They're curious about why certain formulas resonate more than others, how formats like gummies change adherence patterns, and what makes a mushroom blend feel trustworthy. This group is not disillusioned, but deliberate—often spending weeks or months comparing products, reading labels, and seeking experiential data from peers before making a decision.
Pilly Labs sits within this landscape as a brand actively participating in the conversation. By leading with fruiting body extracts, transparent 10:1 concentration ratios, and clean-label ingredients, it provides consumers with answers to many of the questions posed by skeptics, while offering the simplicity and sensory appeal that first drew attention from early adopters. Whether seen as an entry point, a category innovator, or just one option among many, Pilly Labs is navigating the mushroom supplement dialogue with a focus on clarity rather than hype.
About Pilly Labs
Pilly Labs is a wellness brand committed to simplifying the supplement experience through thoughtful formulation, ingredient transparency, and user-first design. Founded on the principle that natural supplementation should be both effective and accessible, Pilly Labs prioritizes clean-label inputs, vegan-friendly formats, and third-party testing across its entire product line. Rather than following trends or adopting flashy branding strategies, the company has built its formulas around what informed consumers increasingly seek—clarity, consistency, and concentrated nutritional value.
Every mushroom supplement produced by Pilly Labs is crafted using 10:1 fruiting body extracts, chosen specifically for their concentration of bioactive compounds and long-standing presence in traditional wellness cultures. The decision to avoid mycelium, synthetic additives, and non-functional fillers is part of a broader commitment to ingredient integrity. Whether presented in capsule or gummy format, each product is manufactured in the United States under GMP-certified standards, with batch-level quality control and transparent labeling.
Pilly Labs also places a strong emphasis on consumer education. Through detailed product pages, clearly defined dosing guidelines, and content that helps users understand their options, the brand offers more than just supplements—it provides a framework for building sustainable wellness habits. This approach has resonated with a diverse audience, from first-time users seeking simple, clean alternatives to experienced wellness enthusiasts integrating mushroom blends into broader health routines.
As the mushroom supplement category continues to grow, Pilly Labs remains focused on refining its formulas, expanding its sourcing partnerships, and listening closely to what modern users value most: trust, simplicity, and the freedom to build wellness routines that feel like a natural part of everyday life.
Contact
Ready to experience the routine-friendly power of functional mushrooms? Explore Pilly Labs Mushroom Gummies and Chaga Capsules today and find the format that fits your lifestyle.
Final disclaimer
This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). Pilly Labs Mushroom Extract Complex and Chaga Mushroom Capsules are not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program.
Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees.
Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
4 hours ago
- Business Upturn
Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) — Booking Health , a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients . The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments. Cervical Cancer Immunotherapy is redefining how doctors treat women diagnosed with stage 4 cervical cancer – offering hope where traditional treatments often fall short. According to global cancer statistics provided by the World Health Organization, cervical cancer is still ranking as the fourth most frequently diagnosed cancer among women worldwide, with over 350,000 deaths reported in 2022 alone. Therefore, the need for more effective therapies is urgent. Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often come with harsh side effects and limited long-term benefit – especially in recurrent or PD-L1-positive cases. This is where immunotherapy is beginning to transform the way we treat cervical cancer. By training the immune system to recognize and destroy cancer cells, this innovative approach is extending survival, improving quality of life, and reshaping the future of gynecologic oncology, according to the American Cancer Society. Leading the way in connecting patients with advanced treatment abroad is Booking Health, a global medical coordination platform that offers access to advanced cervical cancer treatment in the best European clinics. Why Is Stage 4 Cervical Cancer So Hard to Treat? Stage 4 cervical cancer is difficult to treat because it involves metastatic disease, where cancer has spread beyond the pelvis to distant organs, making it less responsive to traditional therapies such as chemotherapy and radiation. In many cases, the disease becomes persistent or recurrent, with fewer effective treatment options available, as reported by the National Cancer Institute. Types of Advanced Cervical Cancer Understanding the different stages helps clarify why some cases are more complex than others: Term Definition Treatment Challenge Locally advanced cervical cancer Cancer has spread beyond the cervix to nearby tissues (e.g., vagina, parametria) but not to distant organs Often treated with chemoradiation, but recurrence risk remains Recurrent cervical cancer Cancer returns after a period of remission May resist previously used therapies and require new approaches Metastatic cervical cancer Cancer spreads to distant organs like lungs, liver, or bones Hard to target; systemic therapies often have limited success Most Common Cervical Cancer Types Squamous cell carcinoma – accounts for 80-90% of cases; originates in the ectocervix Adenocarcinoma – about 10-20% of cases; arises from glandular cells in the endocervix Adenosquamous carcinoma – a rarer subtype with mixed features As reported by Cancer Research UK, each type may behave differently in terms of spread, immune response, and treatment sensitivity. Limitations of Traditional Treatments Standard treatments for advanced cervical cancer include: Chemotherapy: Often platinum-based; effectiveness diminishes over time; Radiation therapy: Can control local disease but may not impact distant metastases; Systemic therapies: Cause significant side effects, with limited survival benefit in persistent cervical cancer. Moreover, the American Cancer Society reports that patients with persistent or metastatic disease often experience poor outcomes, with 5-year survival rates below 20% in stage 4 cases. As such, gynecologic oncology experts have increasingly turned to immunotherapy to improve response rates and extend survival. What Is Immunotherapy and How Does It Work for Cervical Cancer? Immunotherapy for cervical cancer stimulates the body's own immune system to recognize and destroy cancer cells by targeting specific immune pathways. This approach is especially useful for patients with PD-L1–positive, recurrent, or metastatic cervical cancer who may not respond well to conventional treatments. Approach Description Relevance to Cervical Cancer Immune checkpoint inhibitors Block proteins (PD-1, PD-L1) that prevent immune cells from attacking cancer Reactivates exhausted T cells to fight cervical cancer cells Monoclonal antibodies Lab-made antibodies designed to target specific tumor markers Some bind PD-L1 or deliver cytotoxic agents directly to tumor cells Cancer vaccines Stimulate immune response to HPV or tumor-associated antigens Promote lasting T cell activation and memory Adoptive T cell therapy Infuse engineered T cells that can attack tumor cells Under investigation for recurrent cervical cancer The PD-1/PD-L1 Pathway PD-1 is a receptor on T cells that regulates immune response PD-L1 is often overexpressed on cervical cancer cells When PD-L1 binds to PD-1, it 'switches off' the immune attack Checkpoint inhibitors block this interaction – reactivating T cells to destroy cancer cells Why It Matters Many cervical tumors exhibit high PD-L1 expression, making them ideal candidates for immunotherapy. Successful treatment leads to greater T cell infiltration into tumors, enhancing immune surveillance. Patients often experience improved immune response and more durable control of the disease than with chemotherapy alone. This therapeutic shift reflects a broader move toward personalized medicine in gynecologic oncology, targeting tumor-infiltrating lymphocytes and immune checkpoints rather than relying solely on cytotoxic drugs. Findings from the Latest Clinical Trials Recent phase III clinical trials have shown that combining immunotherapy with standard chemotherapy – or using it as a second-line option – can significantly extend survival and delay disease progression in patients with recurrent or metastatic cervical cancer. These studies demonstrate that there has occurred a major shift in how advanced cervical cancer is treated, providing hope to patients who previously had limited options after conventional therapies failed. Highlights from the Trials Patients receiving immunotherapy lived significantly longer than those on chemotherapy alone. Survival benefit was observed regardless of PD-L1 status, especially in recurrent cases after platinum-based treatment. Delays in disease progression gave patients more time with better quality of life. Immune checkpoint inhibitors helped reactivate the immune system's ability to target and destroy cervical cancer cells. Clinical Trial Treatment Type Median Overall Survival (OS) Disease Control Outcome Notes Phase III Study Immunotherapy + Chemo Up to 28.6 months vs 16.5 months Longer survival in all groups Strongest benefit in PD-L1+ patients Randomized Phase III Trial Immunotherapy (2nd-line) 11.7 months vs 8.5 months Benefit seen in all PD-L1 levels Works even after chemo failure * Both studies confirmed survival advantages without significantly higher severe side effects compared to chemotherapy alone. What This Means for Patients For women with recurrent, persistent, or metastatic cervical cancer, these results signal a new standard of care. Immunotherapy is not only more targeted than traditional therapies but also better tolerated, offering: A longer window of disease control (median progression-free survival extended); Improved quality of life with fewer systemic side effects; Hope for those who did not respond to chemotherapy or radiation. This also opens the door for future therapies involving antibody drug conjugates, personalized immune profiling, and combination treatments that utilize both the immune system and conventional medicine. Today, cervical cancer cohorts worldwide are benefiting from a more individualized, immune-driven approach that redefines what is possible after recurrence or metastasis. Who Benefits Most from Immunotherapy in Cervical Cancer? Immunotherapy is most effective for patients with PD-L1-positive, recurrent, or metastatic cervical cancer, particularly when standard treatments like chemotherapy or radiation therapy have failed, as previously mentioned. These patients often have limited options, and immunotherapy provides a targeted approach that can activate the immune system to attack tumor cells more effectively. Common Eligibility Criteria for Immunotherapy Patients who may benefit from immunotherapy typically meet one or more of the following criteria: PD-L1 expression ≥1% (as determined by tumor biopsy); Recurrent or metastatic cervical cancer following standard treatment; Persistent squamous cell carcinoma that does not respond to initial therapies; Evidence of T cell infiltration or active immune cell presence within the tumor; No contraindications for immune checkpoint blockade (e.g., autoimmune diseases). Histology Type Prevalence Response to Immunotherapy Squamous Cell Carcinoma ~80-90% Better overall immune response; more PD-L1 expression; strong T cell infiltration Adenocarcinoma ~10-20% Slightly lower PD-L1 expression; emerging data still promising Adenosquamous/Mixed <5% Limited clinical data; under investigation While both subtypes may benefit, squamous cell carcinoma tends to respond more favorably due to its immunogenicity and higher prevalence of immune markers like PD-L1. Why This Is Important Understanding which patients are most likely to respond helps oncologists personalize therapy, avoid unnecessary toxicity, and improve overall outcomes in metastatic cervical cancer patients. As clinical trials continue to evolve, biomarkers like PD-L1, tumor-infiltrating lymphocytes, and even genomic profiling are playing a larger role in guiding treatment selection. What Are the Current Limitations and Side Effects of Immunotherapy? While immunotherapy is an innovative option in cervical cancer treatment, it is not without limitations. Not all patients experience a positive immune response, and treatment can lead to side effects caused by overstimulation of the immune system. Main Limitations of Immunotherapy for Cervical Cancer Variable response rates: Only patients with specific tumor profiles (e.g., PD-L1-positive tumors or high T cell infiltration) tend to respond. Delayed response: Unlike chemotherapy, benefits may take weeks or months to appear. Immune hyperactivation: Some patients may develop autoimmune-like reactions when the immune system attacks healthy tissue. High costs: Immunotherapy is expensive, and coverage varies widely by country and provider. Limited access: Not all regions offer advanced immune-based therapies or diagnostic testing. Side Effect Type Description Frequency Colitis Inflammation of the colon causing diarrhea Moderate Thyroiditis/Hypothyroidism Immune attack on the thyroid Common Dermatitis or skin rash Immune-related skin inflammation Common Fatigue and joint pain General inflammatory response Mild to moderate Pneumonitis Lung inflammation (rare but serious) Rare Cleveland Clinic highlights that these side effects are often immune-related and differ from those of chemotherapy, which typically causes nausea, hair loss, and bone marrow suppression. Most immune-related reactions are manageable with corticosteroids or immunosuppressive agents when diagnosed early. Importance of Tumor Profiling and Biomarker Testing Before initiating immunotherapy, tumor profiling is crucial. Tests that assess PD-L1 expression, tumor mutational burden, and immune cell markers help determine whether a patient is a good candidate. This ensures that patients treated are those most likely to benefit from therapy while minimizing unnecessary risks. Why Are More Patients Going Abroad for Cervical Cancer Immunotherapy? Many cervical cancer patients choose to go abroad for immunotherapy because of faster access, broader treatment options, and advanced clinical expertise – especially in countries known for innovation in gynecologic oncology. In many parts of the world, patients face long wait times, outdated systemic therapies, or limited access to next-generation immune system-based treatments. This is especially critical for women with advanced or recurrent cervical cancer, where timely intervention can directly affect survival and quality of life. In contrast, specialized cancer centers in countries like Germany offer accelerated treatment pathways, advanced diagnostics, and access to experimental options not yet widely available elsewhere. Primary Reasons Patients Travel Abroad for Treatment Limited access at home: In some countries, immune checkpoint inhibitors and personalized immunotherapy are not yet standard care – or are cost-prohibitive without insurance support. Delays in diagnosis or therapy: Long waitlists for oncology consultations or biopsy testing can result in treatment delays that worsen outcomes. Patients who choose to treat cervical cancer abroad often report improved outcomes, better coordination, and more comprehensive care – especially when guided by experienced facilitators like Booking Health. From Research to Results: How Immunotherapy Extends Life Expectancy Recent clinical advances highlight the growing role of immunotherapy in improving life expectancy for patients with stage 4 cervical cancer. Immune checkpoint inhibitors and other immune-based treatments are showing encouraging results, particularly for recurrent, metastatic, and PD‑L1‑positive cervical cancers, where traditional chemotherapy offers limited benefit. By stimulating the body's own immune system to recognize and attack tumor cells, these therapies have been linked to longer survival and improved progression-free outcomes in international studies. Access to such innovative care remains uneven, prompting patients to seek specialized oncology centers abroad. Through coordination platforms such as Booking Health, individuals are able to connect with leading hospitals in Germany and other countries that offer advanced cervical cancer immunotherapy programs. These multidisciplinary approaches combine personalized treatment planning, modern diagnostics, and targeted immune modulation to address late‑stage disease. As immunotherapy research continues to expand, it represents a significant shift in the management of advanced cervical cancer, giving more women a realistic chance at extended survival and an improved quality of life. Key Takeaways: Immunotherapy's Impact on Advanced Cervical Cancer Immunotherapy offers hope for women with stage 4 cervical cancer, especially when other treatments have failed. It works by strengthening the immune system to recognize and eliminate cancer cells more effectively. Most effective in patients with PD-L1-positive, recurrent, metastatic, or invasive cervical cancer. Recent phase III clinical trials show longer survival and improved median progression-free survival compared to chemotherapy alone. Booking Health connects international patients with leading European hospitals that specialize in cervical cancer immunotherapy and personalized care. These breakthroughs represent a major advancement in the treatment of metastatic cervical cancer – delivering not only longer survival, but also a significantly improved quality of life. To explore your personalized treatment options, contact Booking Health today and take the next step toward advanced cervical cancer care. Side_Effects About Booking Health Booking Health™ is the international platform for rapid access to innovative treatments in the world's leading certified clinics. Our network features over 250 top-tier hospitals across the globe, all distinguished by the exceptional levels of medical accreditation and expertise. By arranging care with the help of Booking Health company, you benefit from comprehensive medical support based on the latest innovations and personalized coordination. We offer cost saving up to 70% compared to direct booking via clinics — all without compromising on quality. Choosing Booking Health means more than just acquiring access to innovative world-class therapy – it means saving valuable time knowing that every detail is handled by professionals. Headquartered in Bad Hönningen, Germany and officially registered in Düsseldorf under HRB 106466, Booking Health proudly consults patients from over 75 countries for over a decade, offering services in 11 languages. Press inquiries Booking Health Lena Hanten [email protected]
Yahoo
4 hours ago
- Yahoo
Disarming a Hidden Killer: Predicting – and Preventing – C. diff Before It Strikes
Institute for Systems Biology researchers use personalized models to forecast gut colonization risk and test targeted probiotic therapies. SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a leading cause of healthcare-associated infections, particularly in hospitals and long-term care facilities. But not everyone who harbors C. diff gets sick – as many as 30-40 percent of us are carrying this bug right now in our guts. C. diff is what scientists call an opportunistic pathogen – capable of causing life-threatening illness, but also capable of existing quietly as a commensal organism in the gut, waiting for the right moment – like after a round of antibiotics – to wreak havoc. What if we could identify the risk before infection takes hold? In a new study published in Cell Systems, researchers from the Institute for Systems Biology (ISB) have developed a powerful, personalized modeling framework to predict whether C. diff is likely to colonize an individual's gut, and to test whether specific probiotic therapies might prevent and/or reverse that colonization. 'C. diff is an opportunist. It can lie in wait in the gut, living benignly, ready to cause disease when conditions allow. If we remove the opportunity, we neutralize the threat,' said Dr. Sean Gibbons, senior author and associate professor at ISB. 'Instead of reacting to disease, this gives us a path to prevent it before it starts.' The team used microbial community-scale metabolic models, developed at ISB by co-senior author Dr. Christian Diener (now an assistant professor at the Medical University of Graz), to simulate how C. diff might behave in more than 15,000 human gut microbiome samples. The models identified three colonization states – high growth, moderate growth, and no growth – based on the unique microbial and metabolic composition of each individual's gut. Using C. diff invasion experiments in synthetic lab-based communities of human gut bacteria, the researchers found that they could accurately predict which communities were susceptible and which were resistant. In addition, they showed that they could accurately predict C. diff colonization in human time series with known C. diff colonization dynamics and in recurrent C. diff infection patients before and after receiving fecal transplants. To better understand the mechanisms of C. diff suppression, they showed that a defined probiotic cocktail (known to resolve recurrent C. diff infections) suppresses C. diff growth by outcompeting it for key metabolites – such as succinate (a dicarboxylic acid), trehalose (a sugar), and ornithine (an amino acid byproduct) – that fuel C. diff's expansion. They also found that the probiotic cocktail was better at suppressing model-predicted C. diff growth in the context of certain microbiota, but not in others – revealing responders and non-responders. By looking at model outputs from naturally resistant microbiota, the authors found that including dominant gram-negative anaerobic genera, like Phocaecola, in the simulated probiotic cocktail further improved model-predicted C. diff growth suppression. These results suggest that personalized, model-predicted probiotics could improve C. diff suppression and reduce the rate of non-responders. 'This work moves us closer to precision probiotics – tailored interventions that account for each person's gut ecosystem,' said Dr. Alex Carr, lead author of the paper and a postdoctoral fellow in ISB's Gibbons Lab. 'The ultimate goal is to decolonize opportunists like C. diff before they cause harm.' The findings have immediate implications for reducing C. diff infections and longer-term potential for proactively managing other opportunistic pathogens. They also offer a blueprint for designing smarter, more targeted probiotic therapies that are personalized to each patient's gut microbiome, although these model-guided interventions will need to be tested in human trials. 'Rather than just flooding the gut with microbes and hoping for the best, we can now use models to match the right probiotic to the right person,' Gibbons said. 'It's a systems biology approach to rationally engineering gut microbiome function, and we think that it has enormous promise for improving the efficacy of microbiome-mediated therapies.' About ISB Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, chronic illness, infectious disease, and more. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit healthcare systems in the United States. Follow us online at and on YouTube, Facebook, LinkedIn, X, Bluesky, and Instagram. CONTACT: Joe Myxter Institute for Systems Biology jmyxter@
Yahoo
7 hours ago
- Yahoo
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the control arm Improvement in PFS was achieved across virtually all subgroups, including those with poor prognostic factors A profound effect was observed in patients with PD-L1 negative tumors treated with Cylembio plus pembrolizumab, HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months for the control arm A trend towards improvement in overall survival (OS) was observed in patients treated with Cylembio plus pembrolizumab (OS not yet mature), HR=0.79 (CI 0.57-1.10) Cylembio plus pembrolizumab was well tolerated, with no new safety signals observed IO Biotech plans to meet with the FDA this fall to discuss the data and next steps for a potential regulatory submission Company to host conference call today at 8:30 a.m. ET to discuss these results NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio® (imsapepimut and etimupepimut, adjuvanted). The trial evaluated Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), vs. pembrolizumab alone as a first-line treatment in 407 patients with unresectable or metastatic (advanced) melanoma. In the study, Cylembio plus pembrolizumab demonstrated clinical improvement in progression free survival compared to pembrolizumab alone, but statistical significance was narrowly missed on the primary endpoint. 'In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio,' said Mai-Britt Zocca, PhD, president and chief executive officer of IO Biotech. 'The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data.' The randomized, open-label study enrolled 407 patients across more than 100 sites worldwide. Patients received either Cylembio in combination with pembrolizumab (n=203) or pembrolizumab alone (n=204). The primary endpoint was PFS as assessed by a blinded independent review committee per RECIST v1.1. The early and sustained separation of PFS curves demonstrated an improvement with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056; threshold for significance p≤0.045]. Based on an intent-to-treat analysis, patients in the study treated with Cylembio in combination with pembrolizumab achieved 19.4 months of median progression free survival compared to 11.0 months in patients treated with pembrolizumab alone. Although not yet mature, a trend toward an improvement in overall survival was also observed [HR 0.79 (95% CI: 0.57-1.10)]; the company expects OS to mature over the next six to nine months. Improvement in PFS was achieved across virtually all subgroups, including those with poor prognostic factors, with a profound effect in patients with PD-L1 negative tumors treated with Cylembio plus pembrolizumab (n=67) compared to patients treated with pembrolizumab monotherapy (n=63), HR: 0.54 (CI 0.35-0.85) (nominal p=0.006), with mPFS of 16.6 months vs. 3.0 months, respectively. Additionally, in a post hoc analysis of patients enrolled in this study without prior anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS compared to patients treated with pembrolizumab monotherapy, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months, respectively. The combination was well tolerated, with no new safety signals observed. Injection site reactions, which were transient and resolved on treatment, were the most commonly reported adverse events in the combination arm, with 56% of patients receiving Cylembio plus pembrolizumab reporting an event. 'In this study, patients treated with Cylembio in combination with pembrolizumab have achieved the longest median PFS ever observed in a Phase 3 clinical study in advanced melanoma, and in the PD-L1 negative population, patients achieved a remarkable 16.6 months of median PFS, compared to 3.0 months in patients treated with pembrolizumab alone,' said Omid Hamid, MD, Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate. 'The significant benefit seen across patients with poor prognostic factors, including PD-L1 negative patients, cannot be overlooked. Given the notable safety profile and the strong clinical effect observed with Cylembio, as well as the unmet need in advanced melanoma patients, Cylembio, if approved, has the potential to become a new standard of care for patients with advanced melanoma.' 'These data show the potential of a therapeutic cancer vaccine in patients with metastatic melanoma,' said Jessica Hassel, MD, Professor at the Department of Dermatology and National Center for Tumor Diseases at the University Hospital Heidelberg, Germany, and lead enrolling investigator for the Phase 3 trial. 'We were thrilled to play such an important part in this study and to have had the ability to offer our patients an investigational therapy that potentially offers improvements in PFS while not adding significant systemic toxicity.' 'Delaying progression and improving survival is the ultimate treatment goal for patients and although overall survival is not yet mature, the trend we are seeing in OS with separation of the curves is encouraging, with a consistent PFS clinical improvement and OS trend favoring the combination arm across virtually all subgroups, with no new safety signals or significant additional systemic toxicity,' said Qasim Ahmad, MD, chief medical officer of IO Biotech. 'We are deeply grateful to the patients for their participation in this study, as well as to investigators and study coordinators whose dedication and collaboration brings us one step closer to delivering a new treatment option to patients in need.' 'Since reporting the positive outcome of our Phase 1/2 study (MM1636) in a similar patient population, we have been eagerly awaiting these results supporting the activity of Cylembio combined with an anti-PD-1 in patients with advanced melanoma,' said Inge Marie Svane, MD, PhD, Professor, Director of the National Center for Cancer Immune Therapy (CCIT) at the Copenhagen University Hospital, Herlev and Principal Investigator in the Phase 3 trial. 'These data provide evidence that a therapeutic cancer vaccine can improve progression free survival in patients with metastatic disease.' Based on these results, IO Biotech plans to meet with the United States (US) Food and Drug Administration (FDA) this fall to discuss the totality of data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma. Additionally, the company plans to present more detailed results from the IOB-013 study at an upcoming medical meeting. Conference Call and Webcast Information IO Biotech management will hold a conference call and webcast today at 8:30 a.m. ET to discuss these clinical data results. Participants can register for the live webcast here. The live webcast and replay will be available through IO Biotech's website here. About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial IOB-013/KN-D18 ( NCT05155254) was an open label, randomized Phase 3 pivotal clinical trial evaluating Cylembio® in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with previously untreated, unresectable or metastatic (advanced) melanoma. Enrollment in the trial was completed by December 2023 with a total of 407 patients enrolled from more than 100 centers across the United States, Europe, Australia, Turkey, Israel and South Africa. The primary endpoint of the study was progression free survival. Secondary endpoints include overall response rate, overall survival, durable objective response rate, complete response rate, duration of response, time to complete response, disease control rate, and incidence of adverse events and serious adverse events (safety and tolerability). Biomarkers in the blood and tumor tissue will also be assessed as exploratory endpoints. The company reported topline results from this trial in the third quarter of 2025. IO Biotech is sponsoring the Phase 3 trial and Merck is supplying pembrolizumab. About Cylembio® Cylembio® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and/or programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) investigating Cylembio in combination with pembrolizumab as first line treatment in patients with advanced solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314) investigating Cylembio in combination with pembrolizumab as neo-adjuvant/adjuvant treatment of patients with solid tumors. Enrollment in the Phase 3 trial was completed rapidly by December 2023 with topline results from this trial reported in the third quarter of 2025. Enrollment in the two ongoing company-sponsored Phase 2 clinical trials is now complete. The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio® is a registered trademark of IO Biotech ApS, a subsidiary of IO Biotech. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the US and Canada). About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit Follow us on our social media channels on LinkedIn and X (@IOBiotech). Forward-Looking Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with the FDA, submission of a BLA, the launch of Cylembio, and statements regarding other current or future clinical trials, their progress, enrollment or results, or the company's financial position or cash runway, are based on IO Biotech's current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. Contacts: InvestorsMaryann Cimino, Director of Investor RelationsIO Biotech, Inc.617-710-7305mci@ MediaJulie beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
